No Data
No Data
New Novus (300765.SZ): Net profit of 79.0613 million yuan in the first quarter decreased by 38.86% year on year
On April 22, GLONGHUI (300765.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 524 million yuan, down 27.08% year on year; net profit attributable to shareholders of listed companies was 79.0613 million yuan, down 38.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 78.171,5 million yuan, down 56.44% year on year; basic earnings per share were 0.0676 yuan.
New Novus (300765.SZ) plans to transfer 10 shares and increase 2 shares to pay 3.2 yuan before interest deduction on April 25
New Novus (300765.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Higher stock prices, two companies raised repurchase prices, and the A-share market picked up or led to a “price increase effect”
① The market picked up, and listed companies began to raise repurchase prices; ② 6 companies in the two markets adjusted their repurchase prices due to rising stock prices; ③ the buybacks of Novus and Nengke Technology are still in progress; ④ ST Shimao has reached the minimum repurchase limit and is still promoting repurchases.
New Novus (300765.SZ): Medication Clinical Trial Approval Notice for Obtaining Antibody Drug Conjugate (ADC) SYS6023
On March 20, GLONGHUI (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” on the antibody drug conjugate (ADC) SYS6023 and will conduct clinical trials in the near future. SYS6023 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, releases toxins, and kills tumor cells. This product is classified as a therapeutic biological product category 1
Express News | New Novus: The holding subsidiary obtains a notice of approval for drug clinical trials
Research Nuggets丨CITIC Construction Investment: New Novartis accelerates the layout of innovative pharmaceuticals, opens up room for future growth, and maintains a “buy” rating
GLONGHUI, March 18 | CITIC Construction Investment Research Report indicates that the revenue of New Novus (300765.SZ) declined for the full year of 2023, mainly due to pressure on caffeine prices, but due to the further decline in raw material costs, increased product gross margin, and steady profit growth, the performance was in line with expectations. The company acquired Jushi Biotech and Shiyao Baike, a subsidiary of Shiyao Group, and introduced a number of innovative assets such as monoclonal antibodies, ADC, mRNA vaccines, and GLP-1. Among them, PD-1 monoclonal antibodies and omalizumab are expected to be approved and contribute revenue this year. The company accelerates the deployment of innovative pharmaceuticals and opens up room for future growth. Maintaining a “buy” rating
No Data